Lescarden Inc.
LCAR · Other OTC · USD
0,00USD
0,00 (0,00 %)Stand 13. Dez., 17:19
Kennzahlen
- Eröffnung
- 0,00
- Vortag
- 0,00
- Tagesspanne
- 0,00 – 0,00
- 52 Wochen
- 0,00 – 0,0001
- Volumen
- 4000
- Ø Volumen
- 24.667
- Börsenwert
- 3181 $
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- -0,7
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Gewinn je Aktie · Erwartet |
|---|
| Gewinn je Aktie · Tatsächlich |
| Abweichung |
| Umsatz · Tatsächlich |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
AHPIQAllied Healthcare Products, Inc.0,0001+1.000,00 %
ARTHArch Therapeutics, Inc.0,0001+0,00 %
CRYOAmerican CryoStem Corporation0,0001−99,75 %
DMTKQDermTech, Inc.0,00010,00 %
EPRSQEPIRUS Biopharmaceuticals, Inc.0,00−99,00 %
ERUCER Urgent Care Holdings, Inc.0,000,00 %
GTHRGeneThera, Inc.0,0001+0,00 %
MDKMMDEChem, Inc.0,00−100,00 %
Über das Unternehmen
Lescarden Inc. operates as a pharmaceutical company, concentrating on the investigation, refinement, and market distribution of medicinal products aimed at managing and curing various illnesses. Its global reach extends across the United States, Europe, and South Korea. The company's premier offering is Catrix Wound Dressing, a product specifically designed for the treatment of persistent lesions, burns, and difficult-to-heal wounds, such as decubitus, venous stasis, and diabetic ulcers. Beyond this, Lescarden provides a range of Catrix-derived solutions for wound and skin care, targeting the aesthetic surgery, dermatological, and medical spa sectors. Furthermore, the organization manufactures dietary supplements, including Bio-Cartilage and Poly-NAG, which is a patented glucosamine polymer. Lescarden also licenses its unique technologies to other enterprises for wider commercial application. Founded in 1960, Lescarden Inc. has its main office situated in New York, New York.
Führung
- William E. LutherChief Executive Officer, Pres, Chief Financial Officer & Director
- CEO
- William E. Luther
- Mitarbeitende
- 1
- Hauptsitz
- New York City, NY, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 4. Jan. 1999
- Website
- lescarden.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.